BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Pfizer/BioNTech Plan mRNA Shingles Vaccine; Moderna Kicks Off EBV Vaccine Trial

  Pfizer and BioNTech are developing a vaccine for the prevention of shingles while Moderna is in a Phase I study of an mRNA vaccine for the Epstein-Barr Virus.

  January 5, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  BioCapital

  Revelar and Twist’s Antibody Neutralizes Delta and Omicron In Vitro

  A bispecific antibody discovered by Twist Bioscience and licensed to Revelar Biotherapeutics neutralizes both the Omicron and Delta variants of SARS-CoV-2 in studies with the live virus.

  January 5, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Several Players Begin 2022 with New Partnerships in Place

  It’s been a busy day for collaboration announcements in the life sciences world. Here are some of the top stories for today.

  January 5, 2022

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Annexon Data Demonstrates Potential of C1q Inhibition in Huntington’s Disease

  An improvement in cUHDRS was observed in more than half of all evaluable patients and was specifically seen in 75% of the evaluable population who showed excess complement activity at baseline.

  January 5, 2022

   · 

  3 min read

   · 

  Sreetama Dutt
• 

  FDA

  Studies Continue to Suggest Milder Omicron; FDA Pauses Domestic Drug Inspections

  Evidence continues to accumulate suggesting that Omicron, although significantly more infectious than previous COVID-19 strains, causes less severe disease.

  January 5, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Biotech Bay

  Predicting the Life Sciences Investment Market in 2022

  Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.

  January 5, 2022

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Business

  5 Life Sciences Companies Raise New Funds for Therapeutic Platforms

  With the beginning of a new year, many biopharmaceutical companies are reporting financial raises to advance their pipelines. BioSpace takes a quick look at some of them.

  January 5, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Virtual JPM Week and Satellite Conferences Tout Increased Engagement Opportunities

  Overall, the decision to hold the conferences virtually again this year is being met with what appears to be a bit of relief.

  January 5, 2022

   · 

  5 min read

   · 

  Gail Dutton
• 

  Business

  4 Companies Ringing in New Year with New CEOs

  Several biopharma companies have adjusted their leadership teams to include new chief executive officers who are expected to guide the companies and their programs into the future.

  January 5, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Business

  Global Roundup: Clover Biopharmaceuticals Builds R&D Center in China

  Biopharma and life sciences companies and organizations provide updates on their businesses and pipelines.

  January 5, 2022

   · 

  6 min read

   · 

  Alex Keown